Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace

Blood culture kit

December 2018—Magnolia Medical Technologies launched its new Best Practice Blood Culture Kit. The kit, developed in partnership with Aero-Med, includes the Steripath Gen2 Initial Specimen Diversion Device, two blood culture bottles, one ChloraSep antiseptic skin prep, and two alcohol prep pads.

Qiagen RNA-seq library prep solutions for NGS

December 2018—Qiagen launched its QIAseq FastSelect RNA Removal Kit, which allows rapid selective removal of RNA classes from any sample, enabling researchers to attain high-quality, reproducible RNA sequencing results.

Study: Guardant360 outperforms tissue biopsy

December 2018—A prospective study in patients with advanced non-small cell lung cancer has demonstrated that the blood-based Guardant360 assay, developed by Guardant Health, identified clinically actionable mutations in nearly twice as many patients as tissue biopsy alone.

Lung cancer mutation detection kit

December 2018—Precipio launched a new ICEme kit using the company’s proprietary Ice-Cold PCR technology. The kit provides physicians with the ability to use a liquid biopsy to identify patients eligible for tyrosine kinase inhibitor therapies through analysis of tumor DNA for these EGFR mutations.

Henry Ford Health partners with Sakura Finetek

November 2018—Detroit-based Henry Ford Health System Pathology and Laboratory Medicine announced a research and development partnership with Sakura Finetek USA to increase the automation level of its core anatomic pathology laboratories.

Qiagen partners with DiaSorin, NeuMoDx

November 2018—Qiagen has introduced an automated, CE-marked workflow for its Quanti-Feron-TB Gold Plus Blood Collection Tubes and a novel DiaSorin Liaison Test on DiaSorin’s Liaison systems. The launch offers Liaison customers high-throughput detection with QFT-Plus as part of the system’s broad menu, and QFT-Plus users will gain an option for full automation of laboratory handling to support TB control efforts. Customers using the new latent TB detection workflow for Liaison systems will purchase the detec-tion components from DiaSorin and the blood collection tube kits from Qiagen. The test is available in Europe and other markets, with an expected U.S. release in 2019 and in China in 2020. In a separate release, Qiagen and NeuMoDx Molecular announced a strategic partnership to commercialize two fully integrated systems for automation of PCR test-ing. Under the agreement, Qiagen will initially distribute the NeuMoDx 288 (for high throughput) and NeuMoDx 96 (for mid-throughput) in Europe and other markets outside of the United States; NeuMoDx will cover the U.S.

Binding Site antigens, antibodies

November 2018—Binding Site’s Immunologicals Group has introduced highly purified Borrelia and chikungunya glycoprotein antigens for use in IVD manufacturing and research applica-tions and as a component within solid phase ELISA-based immunoassay test procedures.

Singulex C. difficile toxin A/B assay

November 2018—Singulex introduced its Singulex Clarity C. diff toxin A/B assay. The assay is a rapid, high-sensitivity, high-precision, one-step solution to C. difficile toxin testing that matches the sensitivity and specificity of cell cytotoxicity neutralization assay, the company reports, “giving it the potential to reduce the false-positives of PCR and the false-negatives of current, less sensitive toxin immunoassays.”

High-speed centrifuge and magnetic stirrer

November 2018—Heathrow Scientific introduced its MagFuge high-speed centrifuge and magnetic stirrer in one unit. The MagFuge features a back-lit digital display and one button programming. Three rotors are included, two for centrifugation (a 12 place for 1.5/2.0 mL tubes and a six place for 5 mL tubes, with adapters for additional tube sizes) and one for stirring that includes two rare earth magnets for high-performance mixing.